Cell line · CVCL_1174
DMS 114
Cancer cell line, Homo sapiens. Thoracic SMARCA4-deficient undifferentiated tumor. 41 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. DMS 114. Cell lines, record CVCL_1174. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1174
On this page
Cell line
As Cellosaurus gives it.
- Name
- DMS 114
- Accession
- CVCL_1174
- RRID
- RRID:CVCL_1174
- Synonyms
- DMS-114, DMS114, Darmouth Medical School 114
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 68Y
- Category
- Cancer cell line
- Diseases
- Thoracic SMARCA4-deficient undifferentiated tumor (NCIt C183115)
- Derived from
- Lung (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Caution | Originally classified as originating from a lung small cell carcinoma, but is reclassified as a thoracic SMARCA4-deficient undifferentiated tumor based on a number of criteria (PubMed=38180245). |
Source Cellosaurus
Papers41
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| FOXA1 drives chemoresistance through activating Wnt pathway in small cell lung cancer. | Transl Lung Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TNIK Overexpression Is Sufficient for Chemoradiation Resistance in Limited-Stage Small Cell Lung Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KDM7B-mediated demethylation of RNF113A regulates small cell lung cancer sensitivity to alkylation damage. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor. | SLAS Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Exosomal Thomsen-Friedenreich Glycoantigen: A New Liquid Biopsy Biomarker for Lung and Breast Cancer Diagnoses. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 41
See all 41 papersRelatives0
None in this release.
Cell banks3
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-2066 | ATCC | |
| CLS | 305364 | CLS | |
| NCI-DCTD | DMS-114 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1174
GET https://conductscience.org/api/cell-lines/v1/CVCL_1174/papers?page=2